Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5–SN38 Antibody–drug Conjugate in Neuroendocrine Prostate Cancer
Abstract
Neuroendocrine prostate cancer (NEPC) is an aggressive form of castration-resistant prostate cancer (CRPC) for which effective therapies are lacking. We previously identified carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) as a promising NEPC cell surface antigen. Here we investigated the scope of CEACAM5 expression in end-stage prostate cancer, the basis for CEACAM5 enrichment in NEPC, and the therapeutic potential of the CEACAM5 antibody–drug conjugate labetuzumab govitecan in prostate cancer.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 01, 2021
- Source ID
- 10.1158/1078-0432.ccr-20-3396
Entities
People
- Ailin Zhang
- Colm Morrissey
- Diana C. DeLucia
- Eva Corey
- Ilsa M. Coleman
- James E. Hopkins
- John K Lee
- Lawrence D. True
- Lisa Ang
- Mark P Labrecque
- Michael C. Haffner
- Michael T Schweizer
- Navonil De Sarkar
- Peter S Nelson
- Rui M Gil da Costa
- Thomas M. Cardillo
Organizations
- Fred Hutchinson Cancer Center
- National Institutes of Health
- United States Department of Defense
- University of Washington